FDA paus­es RAPT Ther­a­peu­tics’ im­munol­o­gy drug stud­ies af­ter pa­tient ex­pe­ri­ences liv­er fail­ure

The FDA has placed a clin­i­cal hold on two tri­als of RAPT Ther­a­peu­tics’ lead im­munol­o­gy can­di­date, zel­necirnon, the biotech an­nounced Tues­day morn­ing.

A pa­tient in a mid-stage atopic der­mati­tis study ex­pe­ri­enced liv­er fail­ure. While the cause is “cur­rent­ly un­known,” the event was deemed “po­ten­tial­ly re­lat­ed to zel­necirnon,” the com­pa­ny said. The pa­tient has since re­ceived a liv­er trans­plant and has re­cov­ered, ac­cord­ing to RAPT ex­ec­u­tives on a Tues­day morn­ing an­a­lyst call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.